Archive | Abstracts

Lean Body Weight versus Total Body Weight as a Covariate for Clearance

Background: When conducting population pharmacokinetic (PK) analyses, total body weight (WT) is often chosen as a covariate to explain between subject variability in clearance (CL). Given that 99% of the body’s clearance takes place within lean tissues, it has been suggested that WT is unlikely to be suitable for obese subjects and lean body weight (LBW) […]

Continue Reading

Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer

Objectives: The primary objective of PK/PD modeling in preparation for the First Human Dose study was to estimate a pharmacologically effective dose range in humans based on preclinical data Methods: Data from tumor growth kinetics Xenograft model in mice and from in vivo target inhibition (IVTI) in rats and in mice were incorporated in our PK/PD […]

Continue Reading

Population pharmacokinetic analysis of morphine in opioid dependent and control subjects

Background:  Pilot data (n=4 per group) suggests methadone maintenance subjects (MMS) may have increased plasma morphine concentrations compared with controls after the same iv dose (1). Morphine is primarily cleared by hepatic glucuronidation, which is inhibited by methadone in vitro (2).  There has been no previous reported investigation of morphine clearance in the presence of buprenorphine.  Targeting of specific […]

Continue Reading

Development of a sufficient design for parameter estimation of fluconazole population pharmacokinetics in HIV patients

Introduction: Fluconazole (FCZ) is an antifungal drug commonly used in HIV patients. A clinician suspected low concentrations of FCZ in HIV patients, which could be due to saturable input (low bioavailability) or nonlinear disposition of the drug. In contrast, the literature suggests that FCZ concentrations are increased in HIV patients. A study found in the literature […]

Continue Reading

Tobramycin in paediatric CF patients – TCI or

Aim: The aim of this study was to i) develop a population pharmacokinetic model for tobramycin in paediatric cystic fibrosis (CF) patients ii) evaluate the influence of covariates, in particular serum creatinine, and iii) test whether tobramycin in CF patients is a candidate for the use in target concentrations intervention (TCI). Methods: Retrospective demographic, dosing and concentration […]

Continue Reading

Comparison of different diagnostic criterion to evaluate nonlinear mixed-effects models

Background: The use of conditional weighted residual (CWRES) and post-hoc ETA (ηph) distribution properties, instead of weighted residual (WRES) distribution properties, as model diagnostic tools when using the first-order conditional (FOCE) algorithm in NONMEM, may give a more accurate picture of if and when a model is miss-specified. Aim: A simulation study was performed to compare these […]

Continue Reading

Nonlinear Mixed Effects Modeling of the Steady-State Pharmacokinetics (PK) of Tipranavir/Ritonavir 500/200 mg bid (TPV/r) for Adult Healthy Volunteers and HIV+ Patients

Background: TPV is the first of a new class of non-peptidic PIs, and has potent activity against multiple PI-resistant HIV. To enhance TPV PK, it is combined with low-dose ritonavir. This abstract reports the results of nonlinear mixed effects modeling to characterize the PK of TPV and to elucidate the effects of demographic parameters on the population […]

Continue Reading

Optimal Designs of Studying Bioimpedance – Design for Nonlinear Mixed Effects Models

Bioelectrical impedance analysis measures the impedance to flow of an alternating electrical current passed through biological tissue. Such impedance measurements allow one to estimate fat-free body mass which is an accepted estimate for lean body weight, considered by some to be a better predictor of drug clearance in the obese than, for example, total body […]

Continue Reading

Different ways of incorporating data below the quantification limit in datasets for parameter estimation

Background: The handling of data below the lower limit of quantification (LLOQ) and the limit of detection (LOD) continues to be a challenge in pharmacokinetic analyses. The LLOQ is the lowest concentration of an analyte in a sample which can be measured with a predefined acceptable level of accuracy and precision (± 20 %). Whereas the […]

Continue Reading

Population Pharmacokinetics of Amikacin in Very Premature Malaysian Neonates

Background: Amikaicn is an aminoglycoside used in the treatment of early onset neonatal sepsis. Nephrotoxicity and ototoxicty induced by aminoglycosides are closely associated with the duration of treatment and the high plasma peak or trough levels. Therapeutic drug monitoring of amikacin has routinely been carried out in neonatal intensive units. Aim: To characterize the population pharmacokinetic parameters […]

Continue Reading